Amgen raises 2026 revenue forecast on strong cholesterol and cancer drug sales
Amgen raised its sales and profit forecast for the third time in 2026 after third-quarter sales rose 8%, led by cholesterol drug Repatha and newer medicines Imdelltra and Uplizna.
